LB Pharmaceuticals Inc Common Stock (LBRX) Stock Price
LBRXStock
$47.73
Market Cap$1.54B
P/E—
PEG Ratio—
Div yield—
Beta1.59
LBRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)80.92%
Price vs S&P 500 (4W)9.87%
VGM Score83.07
LBRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.80 | -$1.71 | -114.20%(-$0.91) | |
| Q4 2025 | -$0.32 | -$0.45 | -42.10%(-$0.13) | |
| Q3 2025 | -$0.57 | -$0.61 | -7.02%(-$0.04) |
LBRX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.23
4.27
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | — | — | A | $47.73 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders including schizophrenia and bipolar depression. Its lead candidate, LB-102, is a novel benzamide antipsychotic with the potential to be the first of its kind approved in the United States, based on amisulpride, an antipsychotic already approved in over 50 countries.